Steven Cohen Verve Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,394,116 shares of VERV stock, worth $12 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,394,116Holding current value
$12 Million% of portfolio
0.02%Shares
4 transactions
Others Institutions Holding VERV
# of Institutions
179Shares Held
70.3MCall Options Held
124KPut Options Held
244K-
Alphabet Inc. Mountain View, CA12.3MShares$106 Million4.92% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$59.2 Million1.46% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$56.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$34.4 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$34.3 Million1.94% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $514M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...